Noninvasive high-frequency oscillatory ventilation versus nasal continuous positive airway pressure in preterm infants with moderate-severe respiratory distress syndrome: A preliminary report

Pediatr Pulmonol. 2017 Aug;52(8):1038-1042. doi: 10.1002/ppul.23755. Epub 2017 Jul 3.

Abstract

Objective: The aim of this study was to compare the effect of noninvasive high-frequency oscillatory ventilation (nHFOV) with nasal continuous positive airway pressure (nCPAP) in preterm infants with moderate-severe respiratory distress syndrome (RDS) after surfactant administration via INSURE (intubation, surfactant, extubation) method on the need for invasive mechanical ventilation (IMV).

Methods: A total of 81 infants with a gestational age (GA) of 28-34 weeks were eligible and were randomized to nCPAP (n = 42) or to nHFOV (n = 39). The need for IMV was the primary outcome. The incidence of bronchopulmonary dysplasia (BPD), occurrence of intraventricular hemorrhage (IVH), and air leaks, and mortality were considered as secondary outcomes.

Result: A total 76 infants finally completed the study. The need for IMV was significantlylower in the nHFOV group compared with the nCPAP group(24.3% vs 56.4%, P < 0.01). The incidence of IVH, air leaks or BPD was similar between the two groups. In addition, the mortality rate was not statistically different.

Conclusion: In this prospective, randomized controlled study, nHFOV significantly reduced the need for IMV as compared with nCPAP in preterm infants with moderate-severe RDS without increase in adverse effects.

Keywords: nasal continuous positive airway pressure; noninvasive high-frequency oscillatory ventilation; preterm infants; randomized trial; respiratory distress syndrome; surfactant.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Bronchopulmonary Dysplasia / etiology
  • Cerebral Intraventricular Hemorrhage / etiology
  • Female
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Male
  • Pulmonary Surfactants / therapeutic use
  • Respiration, Artificial / methods*
  • Respiratory Distress Syndrome, Newborn / drug therapy
  • Respiratory Distress Syndrome, Newborn / therapy*

Substances

  • Pulmonary Surfactants